Sean David to Smoking
This is a "connection" page, showing publications Sean David has written about Smoking.
Connection Strength
6.331
-
Retrospective analysis of changing characteristics of treatment-seeking smokers: implications for further reducing smoking prevalence. BMJ Open. 2016 06 29; 6(6):e010960.
Score: 0.398
-
Gene by Environment Investigation of Incident Lung Cancer Risk in African-Americans. EBioMedicine. 2016 Feb; 4:153-61.
Score: 0.385
-
Systematic review and meta-analysis of opioid antagonists for smoking cessation. BMJ Open. 2014 Mar 14; 4(3):e004393.
Score: 0.339
-
Commentary on Chen et?al. (2014): another step on the road to clinical utility of pharmacogenetics for smoking cessation? Addiction. 2014 Jan; 109(1):138-9.
Score: 0.335
-
Opioid antagonists for smoking cessation. Cochrane Database Syst Rev. 2013 Jun 06; (6):CD003086.
Score: 0.322
-
Genome-wide meta-analyses of smoking behaviors in African Americans. Transl Psychiatry. 2012 May 22; 2:e119.
Score: 0.299
-
Pharmacogenetics of smoking cessation in general practice: results from the patch II and patch in practice trials. Nicotine Tob Res. 2011 Mar; 13(3):157-67.
Score: 0.273
-
Sex differences in TTC12/ANKK1 haplotype associations with daily tobacco smoking in Black and White Americans. Nicotine Tob Res. 2010 Mar; 12(3):251-62.
Score: 0.255
-
Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res. 2007 12; 9(12):1251-7.
Score: 0.220
-
Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics J. 2008 Apr; 8(2):122-8.
Score: 0.209
-
The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. Nicotine Tob Res. 2007 Feb; 9(2):225-31.
Score: 0.207
-
Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res. 2003 Dec; 5(6):935-42.
Score: 0.166
-
Comment on "The public health implications of smoking-induced decreased serum and red blood cell folate levels". Nicotine Tob Res. 2003 Jun; 5(3):397-9.
Score: 0.161
-
Are family physicians willing to use pharmacogenetics for smoking cessation therapy? Fam Med. 2003 Feb; 35(2):83.
Score: 0.157
-
No association between functional catechol O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation. Pharmacogenetics. 2002 Apr; 12(3):265-8.
Score: 0.148
-
Smoking Cessation Pharmacotherapy Based on Genetically-Informed Biomarkers: What is the Evidence? Nicotine Tob Res. 2019 08 19; 21(9):1289-1293.
Score: 0.124
-
Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nat Genet. 2019 02; 51(2):237-244.
Score: 0.119
-
Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. Mol Psychiatry. 2020 10; 25(10):2392-2409.
Score: 0.119
-
Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and Alcohol Use. Biol Psychiatry. 2019 06 01; 85(11):946-955.
Score: 0.118
-
From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. Pharmacogenomics. 2018 07 01; 19(10):861-871.
Score: 0.114
-
The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. Nicotine Tob Res. 2018 03 06; 20(4):403-413.
Score: 0.112
-
Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How. Nicotine Tob Res. 2018 03 06; 20(4):414-424.
Score: 0.112
-
Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. Cochrane Database Syst Rev. 2017 09 08; 9:CD011823.
Score: 0.108
-
Persistent alterations of gene expression profiling of human peripheral blood mononuclear cells from smokers. Mol Carcinog. 2016 10; 55(10):1424-37.
Score: 0.094
-
Smoking behavior and association of melanoma and nonmelanoma skin cancer in the Women's Health Initiative. J Am Acad Dermatol. 2015 Jan; 72(1):190-1.e3.
Score: 0.090
-
Differential Efficacy of Nicotine Replacement Among Overweight and Obese Women Smokers. Nicotine Tob Res. 2015 Jul; 17(7):855-61.
Score: 0.089
-
Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers. Clin Pharmacol Ther. 2014 Aug; 96(2):256-65.
Score: 0.085
-
Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction. 2013 Dec; 108(12):2202-11.
Score: 0.082
-
Smoking and genetic risk variation across populations of European, Asian, and African American ancestry--a meta-analysis of chromosome 15q25. Genet Epidemiol. 2012 May; 36(4):340-51.
Score: 0.075
-
Relationship between amounts of daily cigarette consumption and abdominal obesity moderated by CYP2A6 genotypes in Chinese male current smokers. Ann Behav Med. 2012 Apr; 43(2):253-61.
Score: 0.074
-
Association between daily cigarette consumption and hypertension moderated by CYP2A6 genotypes in Chinese male current smokers. J Hum Hypertens. 2013 Jan; 27(1):24-30.
Score: 0.073
-
Interaction between heavy smoking and CYP2A6 genotypes on type 2 diabetes and its possible pathways. Eur J Endocrinol. 2011 Dec; 165(6):961-7.
Score: 0.072
-
Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women. Drug Alcohol Depend. 2012 Jan 01; 120(1-3):7-13.
Score: 0.071
-
Associations of CYP2A6 genotype with smoking behaviors in southern China. Addiction. 2011 May; 106(5):985-94.
Score: 0.070
-
Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. Pharmacogenomics J. 2012 Feb; 12(1):86-92.
Score: 0.066
-
Genome-wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement. Pharmacogenomics. 2010 Mar; 11(3):357-67.
Score: 0.064
-
Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a meta-analysis and new data. Nicotine Tob Res. 2009 Jan; 11(1):64-76.
Score: 0.059
-
[Smoking cessation]. Praxis (Bern 1994). 2008 Nov 05; 97(22):1185-6.
Score: 0.059
-
Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry. 2008 Jun; 65(6):683-93.
Score: 0.057
-
Chronic cigarette smoking and the microstructural integrity of white matter in healthy adults: a diffusion tensor imaging study. Nicotine Tob Res. 2008 Jan; 10(1):137-47.
Score: 0.055
-
A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine Tob Res. 2008 Jan; 10(1):231-40.
Score: 0.055
-
Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res. 2007 Aug; 9(8):821-33.
Score: 0.054
-
Cross-sectional online survey of clinicians' knowledge, attitudes and challenges to screening and counselling adolescents and young adults for substance use. BMJ Open. 2022 11 22; 12(11):e059019.
Score: 0.039
-
Rare genetic variants explain missing heritability in smoking. Nat Hum Behav. 2022 11; 6(11):1577-1586.
Score: 0.038
-
Should we recommend nicotine replacement therapy? Am Fam Physician. 2001 Jun 01; 63(11):2245-7.
Score: 0.035
-
Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium. Genome Med. 2021 Apr 21; 13(1):66.
Score: 0.035
-
Effects of nicotine deprivation and replacement on BOLD-fMRI response to smoking cues as a function of DRD4 VNTR genotype. Nicotine Tob Res. 2014 Jul; 16(7):939-47.
Score: 0.021
-
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenet Genomics. 2012 Sep; 22(9):695-708.
Score: 0.019